• AmpliFold and the Logic of Capture-and-Release

  2026-10-12

  Ho and colleagues describe AmpliFold, a proof-of-concept lateral flow strategy intended to reduce the dependence of test-line detection on rapid binding kinetics. In a HER2 model system, the reported architecture improved sensitivity by as much as 16-fold in low-receptor-density contexts and 12-fold with a large nanoparticle format, but the evidence remains limited to model analyte experiments in buffer and spiked human serum.

• DOTAP and Self-Amplifying RNA in Cardiac Research

  2026-10-10

  This overview places DOTAP in the broader context of nucleic acid delivery while examining a 2026 preclinical study of self-amplifying Nppa RNA for myocardial infarction. It distinguishes supplier-described applications from the study’s actual lipid nanoparticle formulation, compares evidence across animal models, and outlines key translational limitations.

• TH287 Radiosensitization in CRPC Cells

  2026-10-09

  A 2026 study evaluated TH287 as an MTH1 inhibitor for increasing ionizing-radiation sensitivity in PC-3 and DU-145 castration-resistant prostate cancer cells. The strongest combination effect was reported when irradiation followed initial TH287 exposure by 12 hours, alongside increased apoptosis and cell-cycle disruption, although the evidence remains limited to in vitro models.

• Spray-Drying RNA LNPs: Process and Formulation Insights

  2026-10-09

  A 2025 AAPS PharmSciTech study examined how process and formulation choices can reduce spray-drying stress in RNA-loaded lipid nanoparticles. Its key finding was that Poloxamer 188 helped preserve colloidal stability during drying, while freeze drying provided a lower-shear benchmark for evaluating the approach.

• SGC-CBP30 and Super-Enhancer Biology in LUAD

  2026-10-08

  This overview examines how SGC-CBP30, a CREBBP/EP300 bromodomain inhibitor, may serve as a conceptual research tool for studying enhancer-linked transcription in lung adenocarcinoma. It separates supplier-reported compound properties from the published findings of Zhang et al. and outlines evidence strength, possible applications, and important limits on interpretation.

• Solanesol Product Overview and Evidence Limits

  2026-10-08

  Solanesol is a documented polyisoprenoid alcohol supplied by APExBIO for research use. The available product information defines its chemical identity and describes broad biochemical research contexts, but no matched paper evidence was provided to establish mechanisms, outcomes, or validated assay performance.

• EPZ-6438: Interpreting EZH2 Evidence in Cancer

  2026-10-07

  EPZ-6438 is a selective EZH2 inhibitor with a distinctive evidence base spanning PRC2 biology, HPV-associated cervical cancer, lymphoma, and malignant rhabdoid tumor models. This article explains how to interpret those findings without conflating biochemical potency, epigenetic target engagement, and therapeutic relevance.

• YM 58483 (BTP2): Interpreting SOCE Evidence

  2026-10-07

  YM 58483 (BTP2) is a store-operated calcium entry probe for connecting sustained Ca2+ influx with immune and fibrotic signaling. This article explains how to interpret its CRAC/TRP pathway effects, the ORAI2–JNK–NFAT1–TGF-β1 evidence, and the limits of pharmacologic inference.

• Tricine-SDS-PAGE Gel Preparation Kit Overview

  2026-10-06

  Product identity and stated conceptual scope for APExBIO’s K4136 Tricine-SDS-PAGE gel preparation kit, with no matched peer-reviewed paper evidence available.

• Dual SMAD and Wnt Inhibition for iPSC-RGCs

  2026-10-06

  Chavali et al. reported a chemically defined strategy that combines dual SMAD and canonical Wnt pathway inhibition to generate retinal ganglion cells (RGCs) from induced pluripotent stem cells (iPSCs) with improved yield and reproducibility. The study’s reported purity and functional characterization support the approach as a research platform for glaucoma biology, although the evidence remains in vitro and does not establish therapeutic efficacy.

• Drug Response Metrics in Cancer In Vitro

  2026-10-05

  Hannah Schwartz’s 2022 dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent dimensions of an in vitro drug response. The work supports more careful interpretation of anticancer assays by emphasizing response magnitude, composition, and timing rather than treating a single viability value as a complete measure of drug activity.

• STING Agonist-1 and the B-Cell Immune Circuit

  2026-10-05

  New ESCC research positions STING within a broader CD40–TRAF2–IRF4 network that connects innate sensing with B-cell activation and tertiary lymphoid structure biology. This thought-leadership article examines what that finding establishes, where its evidence remains limited, and how STING agonist-1 can serve as a chemically defined research reagent for hypothesis-driven immunology, inflammation, and cancer studies—without confusing pathway interrogation with clinical validation.

• CHIR 99021 Trihydrochloride in Organoid Research

  2026-10-04

  A source-grounded overview of CHIR 99021 trihydrochloride as a GSK-3 inhibitor, emphasizing intestinal organoid research, stem-cell state regulation, evidence strength, conceptual applications, and important limitations.

• KCNE4-Dependent Modulation of Kv1.3 Pharmacology

  2026-10-03

  The 2024 Biochemical Pharmacology study shows that the auxiliary subunit KCNE4 changes how the Kv1.3 channel is inhibited without apparently changing blocker affinity. Its most important implication is that channel architecture and subunit composition can shape inhibition kinetics, complicating the interpretation of Psora 4 and other Kv1.3 blocker studies in immune cells.

• Regorafenib: From Kinase Map to Causal Biology

  2026-10-02

  Regorafenib (BAY 73-4506) is more than a broad-spectrum kinase inhibitor: it is a useful probe for connecting angiogenesis, invasion, apoptosis, and RRM2–ERK/E2F3 signaling. This article presents a causality-focused framework for cancer biology research that complements, rather than repeats, protocol-centered assay guides.

8723 records 2/582 page Previous Next 12345 下5页 Last page